Malignancy risk in diabetes; a population study based on electronic health records
Abstract
Objective: To document the risk of the most common types of malignancies in people with diabetes compared to the people without diabetes.
Methods: The data source of this study is the national electronic health records system of Türkiye (e-Nabız). We analysed only the data of people over 14 years old in 2019. All the people with ICD-O-3 codes recorded for the first time in 2019 were accepted as new tumour cases. Tumours with /3 behaviour codes were accepted as malignant.
Results: We detected 6,775,054 (10.6%) people with diabetes and 57,167,598 people without diabetes in our database. There were 63,696 new malignant cases in the group with diabetes and 123,662 new malignant cases in the group without diabetes. The total number of malignant tumours was 187,358. All types of major tumours seem to have increased risk. Pancreas cancer has the highest OR (odds ratio), 4.02 (3.71-4.36, 95% confidence interval), and larynx cancer has the lowest OR, 1.29 (1.19-1.41). OR for the presence of any malignancy in a person with diabetes is 1.87 (1.85-1.89).
Conclusion: All major types of malignant tumours have an increased incidence in people with diabetes. The results confirm the presence of a relationship between diabetes and malignancy.
Keywords
Neoplasms, Malignant, Diabetes Mellitus, Electronic Health Records
Supporting Institution
None
Project Number
None
Ethical Statement
Approved by the Clinical Research Ethics Committee of the Medical Faculty of Akdeniz University
Thanks
None
References
- Kim DS, Scherer PE. Obesity, Diabetes, and Increased Cancer Progression. Diabetes Metab J. 2021 Nov;45(6):799-812.
- Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: Stress or viral etiology? Infect Dis-ord Drug Targets. 2008;8:76–87.
- Vulichi SR, Runthala A, Begari N, Rupak K, Chunduri VR, Kapur S, Chippada AR, Sistla DSM. Type-2 diabetes mellitus-associated cancer risk: In pursuit of understanding the possible link. Diabetes Metab Syndr. 2022 Sep;16(9):102591.
- Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne). 2020;11:191.
- Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology Clini-cal Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923-1049.
- Peila R, Rohan TE. Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study. Cancer Epidemiol Bi-omarkers Prev. 2020 Jun;29(6):1107-1119
- Suh S, Kim KW. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. Diabetes Metab J. 2019 Dec;43(6):733-743.
- Ramos-Garcia P, Roca-Rodriguez MDM, Aguilar-Diosdado M, Gonzalez-Moles MA. Diabetes mellitus and oral cancer/oral potentially malignant disorders: A systematic review and meta-analysis. Oral Dis. 2021;27:404-421.
- Yan P, Wang Y, Yu X, Liu Y, Zhang ZJ. Type 2 diabetes mellitus and risk of head and neck cancer subtypes: a systematic re-view and meta-analysis of observational studies. Acta Diabetol. 2021;58:549-565.
- Bae JM. Diabetes History and Gastric Cancer Risk: Different Results by Types of Follow-Up Studies. Asian Pac J Cancer Prev. 2022 May 1;23(5):1523-1528.